Abstract: Enantiomer-pure compounds of general formulas VIIa and VIIb 1

Abstract: The organometallic compound of the present invention is a compound that has bonds between metal atoms and nitrogen atoms or bonds between semimetal atoms and nitrogen atoms, and the content of chlorine in the compound is 200 ppm or less and the content of water is 30 ppm or less.

Abstract: Novel methods, processes and metal complexes attached to a hypoxia-localizing moiety comprising

Abstract: The present invention provides an &agr;-particle-emitting radioisotope chelation complex comprising 225Actinium (225Ac) and 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′,N′,N′,N′-hexaacetic acid (HEHA) (225Ac-HEHA). Also provided is a bifunctional HEHA, and a bifunctional 225Ac-HEHA. The bifunctional HEHA and the bifunctional 225Ac-HEHA can be conjugated to a targeting agent. In view of the above, the present invention provides a method of making HEHA and methods of making a bifunctional HEHA, including a conjugate thereof Also provided are a method of treating disease, a method of treating cancer, a method of decontaminating a sample from 225Ac, a method of decontaminating a person who has been externally contaminated with 225Ac, and a method of detoxifying a person who has internalized 225Ac.

Abstract: The invention relates to indicator molecules for detecting the presence or concentration of an analyte in a medium, such as a liquid, and to methods for achieving such detection. More particularly, the invention relates to copolymer macromolecules containing relatively hydrophobic indicator component monomers, and hydrophilic monomers, such that the macromolecule is capable of use in an aqueous environment.

Abstract: The present invention provides a process of preparation of naphthochlorins and other chlorins with annelated ring systems useful for photodynamic therapy and the compounds themselves. The method for producing naphthochlorin compounds include contacting compounds such as meso-(2′-hydroxymethyl)phenyl porphyrin or meso-(2′-N,N,N-trialkylaminomethyl)phenyl porphyrin precursors with at least one acid catalyst at sufficient temperature for a sufficient time to yield the desired conversion. In a similar manner chlorins possessing annelated ring systems may be made from compounds such as meso-(2′-hydroxymethyl)aryl porphyrins or meso-(2′-N,N,N-trialkylaminomethyl)phenyl porphyrin. The procedures described herein provide new routes for synthesizing naphthochlorins and chlorins with annelated ring systems.

Abstract: The invention relates to polymeric phosphinic acids and their salts of the formula (I) 1

Abstract: Lanthanum compounds are provided having general formulas (I) Rni+Yin− and (II) Rb+Yb− which may be used as medicaments in the prophylaxis and/or treatment of cancer diseases.

Abstract: This invention relates to a radiation detection device for detecting ionizing beam discharges such as gamma rays, x-rays, electron beams, charged particle beams and neutral particle beams. Specifically, it relates to a radiation detection device which can measure radiations which exist for a very short time (of the order of subnanoseconds or less) from the appearance of photoemission to extinction.

Abstract: A process for carrying out a chemical reaction which is catalysed by one or more metal or hydrogen fluoroalkyl-sulfonylated compound which process comprises carrying out said reaction in the presence of an ionic liquid or in solvent-free conditions.

Abstract: A metallocene catalyst in which the metal is coordinated by a &eegr;5 cyclopentadienyl ligand which forms part of an indenyl or indenyloid moiety, characterised in that said moiety is directly or indirectly substituted at the 4-, 5-, 6- or 7-position by a pendant siloxy or germyloxy group.

Abstract: The present invention provides luminescent metal ion complexes for use in a wide range of biological and chemical studies. The luminescent metal ion complexes of the invention comprise a metal ion chelating component covalently bound to a carrier molecule. Also provided are methods of making and using the luminescent metal ion complexes.

Abstract: Stable rare earth tris (organophosphate) solutions comprise a rare earth tris (organophosphate) and a hydrocarbon solvent. From about 2% to about 10% rare earth element, preferably from about 3% to about 8%, is present in the solutions. The rare earth tris (organophosphate) solutions are stable from precipitation of the rare earth tris (organophosphate) for at least about fifteen (15) days, preferably for at least about twenty (20) days and most preferably at least about thirty (30) days. A process for preparing these solutions is described herein. A stabilizing additive, acid, glycol or mixtures thereof, is utilized to inhibit precipitation. The molar ratios of free acid, glycol and/or water to the rare earth element are controlled to inhibit precipitation.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: A metal bis-triflimide compound having the formula: [Mx]n+[(N(SO2CF3)2)(nx-yz)](nx-yz)−[Ly]z− where M is a metal selected from the metals in groups 5 to 10, 12 and 14 to 16 and Cu, Au, Ca, Sr, Ba, Ra, Y, La, Ac, Hf, Rf, Ga, In, Tl, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Lu and the actinides; L is a negative or neutral ligand; n is 2,3,4,5,6,7 or 8; x is greater than or equal to 1 y is 0,1,2,3,4,5,6,7 or 8; and z is 0,1,2,3 or 4.

Abstract: Bridged catalyst component in which a bridge spans two cylcopentadienyl or aromatic groups. The Cp or aromatic groups are attached to the same or different heteroatoms of the bridge, which heteroatoms are also bonded to a metal. A catalyst system can be made by contacting the bridged component with a cocatalyst. Polymerization of olefins can be catalyzed by the system.

Abstract: The present invention covers radiosensitizers containing as an active ingredient halogenated derivatives of boronated porphyrins containing multiple carborane cages having the structure which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron—capture therapy and photodynamic therapy. The present invention also covers methods for using these radiosensitizers in tumor imaging and cancer treatment.

Abstract: Compositions are disclosed comprising (a) a metal chelate wherein the metal is selected from the group consisting of europium, terbium, dysprosium, samarium osmium and ruthenium in at least a hexacoordinated state and (b) a compound having a double bond substituted with two aryl groups, an oxygen atom and an atom selected from the group consisting of oxygen, sulfur and nitrogen wherein one of the aryl groups is electron donating with respect to the other. Such composition is preferably incorporated in a latex particulate material. Methods and kits are also disclosed for determining an analyte in a medium suspected of containing the analyte. The methods and kits employ as one component a composition as described above.

Abstract: The invention concerns olefin polymerization catalyst component comprising an organometallic compound of general formula I wherein: M is a transition metal of groups 3, 4-10, lanthanide or actinide of the periodic table of the elements; each R is independently a structural bridge rigidly connecting two ligands L1, L2 and L3 and is constituted by 1 to 4 chain atoms selected from carbon, silicon, germanium, oxygen, boron; m, n and o are 0 or 1, with the proviso that m+n+o is 2 or 3; L1 is a ligand of the cyclopentadienyl type or is isolobal to cyclopentadienyl, L2 is a ligand of the cyclopentadienyl type or is isolobal to cyclopentadienyl, or a monovalent anionic ligand selected from the group consisting of N, P, B when m+n=2, it is selected from the group consisting of NR1, PR1, BR1, O and S when m+n=1; L3 is a monovalent anionic ligand selected from the group consisting of N, P, B when n+o=2, it is selected from the group consisting of NR1, PR1

Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.

Abstract: Bridged metallocene catalyst component in which a bridge spans two cyclopentadienyl groups, which Cp groups are attached to same or different heteroatoms of the bridge, which heteroatoms are also bonded to the metal. A catalyst systems is made by contacting the bridged component with a cocatalyst. Polymerization of olefins in catalyzed by the system.

Abstract: Emissive phosphorescent organometallic compounds that produce electroluminescence and organic light emitting devices employing such emissive phosphorescent organometallic compounds are provided. More specifically the present invention is directed to novel primarily non-emitting ligands which produce a blue shift in emitted light when associated with a cyclometallated ligand.

Abstract: This invention provides a cochleate and nano-cochleate systems wherein the agents bridging lipid bilayer are organic multi-valent cations. This invention also provides a method for preparing the cochleate system comprising direct cochleation and hydrogel-isolated procedure. The preparation method comprises using the charge ration between the bridging agents and lipids to control the particle sizes. This cochleate or nano-cochleate system may be used for microencapsulation and delivery of therapeutics wherein the therapeutic agents are loaded in the cochleate structure as the bridging agents between lipid bilayers. Finally, this invention provides other uses of these new cochleate and nano-cochleate systems.

Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted.

Abstract: The present invention concerns new compounds comprising a branched linker and their use for producing conjugates for applications in diagnostic or therapeutic methods.

Abstract: &bgr;-diketone fluorescent tags are disclosed, particularly those enabling the use of excitation energy in the near visible or visible spectrum. In some cases, these tags allow the use of cost-effective excitation devices such as LED's. The compounds form fluorescent chelates (complexes) with lanthanide (III) rare earth metal ions (such as Eu3+). The fluorescent complex may be included in a latex microparticle, such as a styrene latex particle. Ideally, the complex has an absorption maximum &lgr; equal to or greater than 360 nm, and the compound is characterized by a pKa<9.0. Kits and methods for detecting target molecules (e.g. immunoassays) are also disclosed. Such methods and kits typically use a ligand for binding to the target molecule and a labeling agent attached to the ligand. The fluorescent complexes described above are at least part of the labeling agent.

Abstract: A complex of a Group 3-10 metal, said complex comprising a cyclic group containing delocalized electrons, a bridging group connecting he metal with the cyclic group, and acetylene or a derivative thereof

Abstract: A new class of polychelants, their chelates with metal ions and their physiologically acceptable salts, useful, either as they are or in association or formulation with other components, for diagnostic imaging as general or specific contrast agents for specific tissues, organs or body compartments.

Abstract: Amines having an unsaturated bond can be introduced into the organic layer of organic-inorganic laminar perovskite compounds comprising a metal halide and an organic amine, and the organic layer can be polymerized by applying external energy such as by irradiating with UV light or radiation. In this way, the quantum well structure is stabilized. The organic-inorganic laminar perovskite polymer compound is produced by cross-linking unsaturated bonds of an organic-inorganic laminar perovskite compound represented by the general formula (RNH3)2MX4 (in the formula, R is a hydrocarbon group having an unsaturated bond, X is a halogen or mixture of same, M is Group IVa metal, Eu, Cd, Cu, Fe, Mn or Pd). R is represented by CH3(CH2)nC≡C—C≡CCH2 (n=2-14). It is preferred that M is Pb, and X is a bromine atom.

Abstract: A subject of the present invention is new compounds having a lanthanide and having a tridentate ligand, a process for their preparation and their use in particular as polymerization catalysts.

Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.

Abstract: Trimetallic nitride endohedral metallofullerene derivatives and their preparation are described. The trimetallic nitride endohedral metallofullerene derivatives have the general formula A3-nXn@Cm(R) where n ranges from 0 to 3, A and X may be trivalent metals and may be either rare earth metal or group IIIB metals, m is between about 60 and about 200, and R is preferably an organic group. Derivatives where the R group forms cyclized derivatives with the fullerene cage are also described.

Abstract: Described herein are novel indicator molecules of general formula (1): 1

Abstract: The present invention relates to novel hetero-multimetallic catalyst precursors and catalysts for the polymerization of olefins.

Abstract: The invention provides low molecular weight or polymeric organic materials in which at least one hydrogen atom is replaced by a group of the formula (A) 1

Abstract: A composite metal polybasic salt containing a trivalent metal and magnesium as metal components and having a novel crystal structure, and a method of preparing the same. The invention further deals with a composite metal polybasic salt which has anion-exchanging property, which by itself is useful as an anion-exchanger, capable of introducing anions suited for the use upon anion-exchange, and finds a wide range of applications, and a method of preparing the same. The composite metal polybasic salt has a particular chemical composition and X-ray diffraction peaks, and further has a degree of orientation (Io) of not smaller than 1.5.

Abstract: A method for denaturing allergens with an effective amount of a rare earth metal salt.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such resins may be used in dental restorative materials to help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.

Abstract: The present invention relates to a process for stereoselective or regioselective chemical synthesis which generally comprises reacting a nucleophile and a chiral or prochiral cyclic substrate in the presence of a non-racemic, chiral catalyst to produce a stereoisomerically- and/or regioisomerically-enriched product. The present invention also relates to hydrolytic kinetic resolutions of racemic and diastereomeric mixtures of epoxides.

Abstract: The present invention relates to novel complexes of (transition) metals containing ligands having phosphinimine centers bonded to the (transition) metal.

Abstract: A cationic Group 3 or Lanthanide metal complex for coordination polymerization of olefins is disclosed. The precursor metal complex is stabilized by an anionic multidentate ancillary ligand and two monoanionic ligands. The ancillary ligand and the transition metal form a metallocycle having at least five primary atoms, counting any &pgr;-bound cyclopentadienyl group in the metallocycle as two primary atoms. Olefin polymerization is exemplified.

Abstract: The invention provides metallocene catalyst systems for the controlled polymerization of alkenes to a wide variety of polyolefins and olefin coplymers. Catalyst systems are provided that specifically produce isotactic, syndiotactic and steroblock polyolefins. The type of polymer produced can be controlled by varying the catalyst system, specifically by varying the ligand substituents. Such catalyst systems are particularly useful for the polymerization of polypropylene to give elastomeric polypropylenes. The invention also provides novel elastomeric polypropylene polymers characterized by dyad (m) tacticities of about 55% to about 65%, pentad (mmmm) tacticities of about 25% to about 35%, molecular weights (MW) in the range of about 50,000 to about 2,000,000, and have mmrm+rrmr peak is less than about 5%.

Abstract: A catalyst in a solid state for polymerization of a conjugated diene or copolymerization of a conjugated diene and an aromatic vinyl compound, which comprises a metallocene-type cation complex of a rare earth metal compound. The catalyst typically is a trivalent rare earth metal compound represented by the general formula (I): RaMXb wherein M represents a rare earth metal; R represents cyclopentadienyl group, a substituted cyclopentadienyl group, indenyl group, a substituted indenyl group, fluorenyl group, or a substituted fluorenyl group; X represents an anion; symbol “a” represents an integer of 1 or 2; and symbol “b” represents an integer of 1 or 2.

Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.

Abstract: New ligands and compositions with bridged bis-aromatic ligands are disclosed that catalyze the polymerization of monomers into polymers. These catalysts with metal centers have high performance characteristics, including higher comonomer incorporation into ethylene/olefin copolymers, where such olefins are for example, 1-octene, propylene or styrene. The catalysts also polymerize propylene into isotactic polypropylene.

Abstract: The invention relates to a method for producing racemic metallocene complexes by reacting bridged or non-bridged transition metal complexes with cyclopentadienyl derivatives of alkaline or alkaline earth metals and optionally, subsequently substituting the phenolate ligands.

Abstract: Novel methods, processes and metal complexes attached to a hypoxia-localizing moiety comprising

Abstract: A cationic Group 3 or Lanthanide metal complex for coordination polymerization of olefins is disclosed. The precursor metal complex is stabilized by a monoanionic bidentate ancillary ligand and two monoanionic ligands. The ancillary ligand and the transition metal form a metallocycle having at least five primary atoms, counting any &pgr;-bound cyclopentadienyl group in the metallocycle as two primary atoms. Olefin polymerization is exemplified.

Abstract: Surprisingly stable olefin polymerization catalysts and co-catalysts formed from hydroxyaluminoxanes are revealed. In one embodiment of the invention, a solid composition of matter is formed from a hydroxyaluminoxane and a treating agent, whereby the rate of OH-decay for the solid composition is reduced as compared to that of the hydroxyaluminoxane. Gelatinous compositions of matter formed from hydroxyaluminoxane and having similar stability characteristics are also disclosed. Processes for converting a hydroxyaluminoxane into a such compositions of matter, supported catalysts formed from such co-catalyst compositions of matter, as well as methods of their use, are described.

Abstract: Methods and compositions are provided for detecting changes in membrane potential in membranes biological systems.